Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Esplugues De Llobregat – page 4

334 clinical trials in Esplugues De Llobregat, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Esplugues De Llobregat at a glance
334
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

334 trials in Esplugues De Llobregat

Open in trial search

Cardiomyopathy

Recruiting

A Study Comparing Gadopiclenol and Gadoterate Meglumine for Heart MRI Scans in Children with Congenital Heart Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Meglumine Gadoterate
  • Sponsor:Fundacio Sant Joan De Deu

Mite allergy

Recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Myasthenia gravis

Recruiting

A study testing how inebilizumab works and how safe it is in children and teenagers aged 2 to 17 years with generalized myasthenia gravis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Haemophilia

Recruiting

A study testing fitusiran to prevent bleeding in boys aged 1 to 11 years with hemophilia A or B with or without inhibitors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Fitusiran
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neurofibromatosis+1

Recruiting

A study of mirdametinib for infants and toddlers under 24 months of age with neurofibromatosis type 1 associated plexiform neurofibromas

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Sponsor:Merck Healthcare KGaA

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Major depression

Recruiting

A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Esketamine
  • Sponsor:Janssen Cilag International

Beta haemolytic streptococcal infection

Recruiting

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
  • Sponsor:Pfizer Inc.

Congenital leptin deficiency

Recruiting

A Study of Mibavademab for Weight Loss in Children, Adolescents and Adults with Obesity Caused by LEP Gene Mutations

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mibavademab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Still's disease

Recruiting

A Study of MAS825 in Children and Adults with Still's Disease to Test How Well It Works and How Safe It Is

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Igg1 Monoclonal Antibody Against Human Il-1 Beta And Human Il-18
  • Sponsor:Novartis Pharma AG

Chronic graft versus host disease

Recruiting

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Esplugues De Llobregat

What the registry says about research in the country

01 Pediatric Oncology Research

Innovative clinical trials focusing on pediatric cancers include studies for neuroblastoma, hepatic tumors, and various sarcomas. Research efforts target both primary and refractory disease states.

  • High-risk neuroblastoma treatments
  • Hepatoblastoma and hepatocellular carcinoma therapies
  • Ewing sarcoma management

Studies are evaluating novel therapeutic approaches for improving patient outcomes in challenging pediatric cancers.

02 Rare Genetic Disorders

Research initiatives addressing rare genetic conditions are exploring new treatment options for conditions affecting children and young adults.

  • Duchenne Muscular Dystrophy
  • Angelman Syndrome
  • Prader-Willi Syndrome
  • Hunter Syndrome

These trials aim to evaluate innovative therapies targeting specific genetic mechanisms.

03 Respiratory and Immunological Studies

Clinical research focusing on respiratory conditions and immunological responses, particularly in pediatric populations.

  • RSV prevention in high-risk infants
  • Allergic rhinitis treatments
  • Bronchopulmonary dysplasia management

Studies emphasize both preventive measures and therapeutic interventions for respiratory conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.